Book contents
- A Clinician’s Guide to Cannabinoid Science
- Reviews
- A Clinician’s Guide to Cannabinoid Science
- Copyright page
- Dedication
- Contents
- Preface
- Section 1 An Introduction to Cannabinoid Science
- Chapter 1 An Introduction to the Botany and History of Cannabinoids
- Chapter 2 Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- Chapter 3 The Endocannabinoids
- Chapter 4 Approved Cannabinoid Medicines for Therapeutic Use
- Chapter 5 The Safety of Phytocannabinoids and Cannabinoids in Clinical Practice
- Section 2 Potential Therapeutic Uses of Cannabinoids in Clinical Practice
- Index
- References
Chapter 1 - An Introduction to the Botany and History of Cannabinoids
from Section 1 - An Introduction to Cannabinoid Science
Published online by Cambridge University Press: 12 October 2020
Book contents
- A Clinician’s Guide to Cannabinoid Science
- Reviews
- A Clinician’s Guide to Cannabinoid Science
- Copyright page
- Dedication
- Contents
- Preface
- Section 1 An Introduction to Cannabinoid Science
- Chapter 1 An Introduction to the Botany and History of Cannabinoids
- Chapter 2 Δ9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD)
- Chapter 3 The Endocannabinoids
- Chapter 4 Approved Cannabinoid Medicines for Therapeutic Use
- Chapter 5 The Safety of Phytocannabinoids and Cannabinoids in Clinical Practice
- Section 2 Potential Therapeutic Uses of Cannabinoids in Clinical Practice
- Index
- References
Summary
Plants have been a plentiful source of useful drugs and remedies throughout human history. In the early nineteenth century Friedrich Sertürner isolated morphine from the opium plant. By 1827, morphine was marketed by Merck in Germany and the origins of the modern pharmaceutical industry began. Over the remainder of the nineteenth century further advances in organic chemistry led to identification of other drugs from plant material. Examples of important medicines developed from plants included quinine from the bark of the cinchona tree for the treatment of malaria and salicylic acid from the willow tree that eventually led to the development of aspirin (Anderson, 2005).
- Type
- Chapter
- Information
- A Clinician's Guide to Cannabinoid Science , pp. 1 - 12Publisher: Cambridge University PressPrint publication year: 2020
References
Abel, E. L. (1980) Marijuana: The First Twelve Thousand Years. New York: Plenum Press.Google Scholar
Alger, B. E. and Kin, J. (2011) ‘Supply and demand for endocannabinoids’, Trends in Neurosciences, 34, 304–315.CrossRefGoogle ScholarPubMed
Anderson, S. (ed.) (2005) Making Medicines: A Brief History of Pharmacy and Pharmaceuticals. London: Pharmaceutical Press.Google Scholar
Derocq, J. M. et al. (1998) ‘The endogenous cannabinoid anandamide is a lipid messenger activating cell growth via a cannabinoid receptor-independent pathway in hematopoietic cell lines’, FEBS Letters, 425(3), 419–425.Google Scholar
Devane, W. A. et al. (1988) ‘Determination and characterization of a cannabinoid receptor in rat brain’, Molecular Pharmacology, 34(5), 605–613.Google ScholarPubMed
Devane, W. A. et al. (1992) ‘Isolation and structure of a brain constituent that binds to the cannabinoid receptor’, Science, 258(5090), 1946–1949.CrossRefGoogle Scholar
Di Marzo, V., De Petrocellis, L. and Bisogno, T. (2005). ‘The biosynthesis, fate and pharmacological properties of endocannabinoids’, Handbook of Experimental Pharmacology, 168, 147–185. doi:10.1007/3-540-26573-2_5.CrossRefGoogle Scholar
Dinh, T. P., Kathuria, S. and Piomelli, D. (2004) ‘RNA interference suggests a primary role for monoacylglycerol lipase in the degradation of the endocannabinoid 2-arachidonoylglycerol’, Molecular Pharmacology, 66(5), 1260–1264.Google Scholar
Gaoni, Y. and Mechoulam, R. (1964) ‘Isolation, structure and partial synthesis of an active constituent of hashish’, Journal of the American Chemical Society, 86(8), 1646–1647.CrossRefGoogle Scholar
Hanus, L. et al. (2001) ‘2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor’, Proceedings of the National Academy of Sciences of the United States of America, 98, 3662–3665.CrossRefGoogle ScholarPubMed
Howlett, A. C., Qualy, J. M. and Khachatrian, L. L. (1986) ‘Involvement of Gi in the inhibition adenylate cyclase by cannabimimetic drugs’, Molecular Pharmacology, 29(3), 307–313.Google ScholarPubMed
Huang, S. M. et al. (2002) ‘An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors’, Proceedings of the National Academy of Sciences of the United States of America, 99, 8400–8405.CrossRefGoogle ScholarPubMed
Huestis, M. A. (2005). ‘Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol’, Handbook of Experimental Pharmacology, 168, 657–690.CrossRefGoogle Scholar
Huestis, M. A. and Smith, M. L. (2014) ‘Cannabinoid pharmacokinetics and disposition in alternative matrices’, in Pertwee., R. G. (ed.), Handbook of Cannabis. Oxford: Oxford University Press. pp. 296–318.Google Scholar
Maccarrone, M., Dainese, E. and Oddi, S. (2010) ‘Intracellular trafficking of anandamide: new concepts for signaling’, Trends in Biochemical Sciences, 35, 601–608.CrossRefGoogle ScholarPubMed
Mead, A. P. (2014) ‘International control of cannabis’, in Pertwee, R. G. (ed.), Handbook of Cannabis. Oxford: Oxford University Press. pp. 44–64.Google Scholar
Mechoulam, R. et al. (1988). ‘Enantiomeric cannabinoids: stereospecificity of psychotropic activity’, Experientia, 44(9), 762–764.CrossRefGoogle ScholarPubMed
Mechoulam, R. et al. (2014). ‘Early phytocannabinoid chemistry to endocannabinoids and beyond’, Nature Reviews Neuroscience, 15(11), 757–764.CrossRefGoogle ScholarPubMed
Munro, S., Thomas, K. L. and Abu-Shaar, M. (1993) ‘Molecular characterization of the peripheral receptor for cannabinoids’, Nature, 365(6441), 61–65.Google Scholar
Nestler, E. J., Hyman, S. E. and Malenka, R. C. (2001) Molecular Neuropharmacology. A Foundation for Clinical Neuroscience. New York: McGraw-Hill Company.Google Scholar
Pacher, P. and Mechoulam, R. (2011) ‘Is lipid signaling through cannabinoid 2 receptors part of a protective system?’, Progress in Lipid Research, 50, 193–211.CrossRefGoogle ScholarPubMed
Parker, L. A. (2017) Cannabinoids and the Brain. Cambridge, MA: MIT Press. p. 29.CrossRefGoogle Scholar
Pertwee, R. G. et al. (2005). ‘Evidence that (-)-7-hydroxy-4-dimethylheptyl-cannabidiol activates a non-CB (1), non-CB (2), non-TRPV1 target in the mouse vas deferens’, Neuropharmacology, 48(8), 1139–1146.CrossRefGoogle Scholar
Porter, A. C. et al. (2002) ‘Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor’, Journal of Pharmacology and Experimental Therapeutics, 301, 1020–1024.CrossRefGoogle ScholarPubMed
Potter, D. J. (2014) ‘Cannabis horticulture’, in Pertwee, R. G. (ed.), Handbook of Cannabis. Oxford: Oxford University Press. pp. 65–88.CrossRefGoogle Scholar
Price, M. R. et al. (2005) ‘Allosteric modulation of the cannabinoid CB1 receptor’, Molecular Pharmacology, 68(5), 1484–1495. doi:10.1124/mol.105.016162.Google Scholar
Ryberg, E. et al. 2007. ‘The orphan receptor GPR55 is a novel cannabinoid receptor’, British Journal of Pharmacology, 152(7), 1092–1101.CrossRefGoogle ScholarPubMed
Starowicz, K. and Przewlocka, B. (2012) ‘Modulation of neuropathic pain related behavior by the spinal endocannabinoids/endovanilloid system’, Philosophical Transactions of the Royal Society of London. Series B Biological Sciences, 367, 3286–3299.CrossRefGoogle ScholarPubMed
Sugiura, T. et al. (1995) ‘Arachidonoylglycerol: a possible endogenous cannabinoid ligand in brain’, Biochemical and Biophysical Research Communications, 215, 89–95.CrossRefGoogle ScholarPubMed
Sugiura, T. et al. (2002) ‘Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible significance’, Prostaglandins, Leukotrienes and Essential Fatty Acids, 66, 173–192.CrossRefGoogle Scholar